OTSUKA PHARMACEUTICAL DEVELOPMENT & COMMERCIALIZATION, INC.
🇺🇸United States
A Safety Study to Evaluate the Use and Effectiveness of a Topical Ointment to Treat Adults With Atopic Dermatitis
Phase 1
Completed
- Conditions
- Atopic Dermatitis
- Interventions
- First Posted Date
- 2012-10-05
- Last Posted Date
- 2014-01-17
- Target Recruit Count
- 92
- Registration Number
- NCT01702181
Open-label, Extension Study of Aripiprazole Intramuscular Depot (OPC-14597, Lu AF41155) in Patients With Schizophrenia
- First Posted Date
- 2012-09-11
- Last Posted Date
- 2015-03-31
- Target Recruit Count
- 74
- Registration Number
- NCT01683058
Phase 1 Study to Assess the Safety/Tolerability of Brexpiprazole as Adjunctive Therapy in Elderly Subjects With Major Depressive Disorder
- First Posted Date
- 2012-08-22
- Last Posted Date
- 2016-02-04
- Target Recruit Count
- 18
- Registration Number
- NCT01670279
- Locations
- 🇺🇸
Accurate Clinical Trials, Kissimmee, Florida, United States
🇺🇸Miami Jewish Health System, Miami, Florida, United States
🇺🇸St. Louis Clinical Trials, St. Louis, Missouri, United States
Efficacy, Safety, and Tolerability of Brexpiprazole (OPC-34712) as Maintenance Treatment in Adults With Schizophrenia
- First Posted Date
- 2012-08-20
- Last Posted Date
- 2017-01-13
- Target Recruit Count
- 524
- Registration Number
- NCT01668797
Trial of Aripiprazole Intramuscular Depot (OPC-14597, Lu AF41155) in the Acute Treatment of Adults With Schizophrenia
- First Posted Date
- 2012-08-13
- Last Posted Date
- 2015-02-16
- Target Recruit Count
- 340
- Registration Number
- NCT01663532
Multicenter, Open-label, Safety and Tolerability Study
- First Posted Date
- 2012-07-25
- Last Posted Date
- 2015-10-29
- Target Recruit Count
- 244
- Registration Number
- NCT01649557
- Locations
- 🇺🇦
Otsuka Investigational Site, Vinnytsya, Ukraine
An Open Label Study of Aripiprazole Intramuscular Injection in Subjects With Schizophrenia
- First Posted Date
- 2012-07-20
- Last Posted Date
- 2014-07-31
- Target Recruit Count
- 37
- Registration Number
- NCT01646827
- Locations
- 🇺🇸
Collaborative Neuroscience Network, Inc., Garden Grove, California, United States
🇺🇸CNRI - San Diego, San Diego, California, United States
🇺🇸Community Clinical Research, Inc., Austin, Texas, United States
Efficacy, Safety, and Tolerability of an Intramuscular Formulation of Aripiprazole (OPC-14597) as Maintenance Treatment in Bipolar I Patients
Phase 3
Completed
- Conditions
- Bipolar I Disorder
- Interventions
- Drug: Intramuscular (IM) Depot AripiprazoleDrug: Intramuscular (IM) Depot Placebo
- First Posted Date
- 2012-03-30
- Last Posted Date
- 2018-08-24
- Target Recruit Count
- 731
- Registration Number
- NCT01567527
Safety and Tolerability Trial of Aripiprazole IM Depot Treatment in Adult Subjects With Schizophrenia Stabilized on Oral Antipsychotics Other Than Aripiprazole
- First Posted Date
- 2012-03-13
- Last Posted Date
- 2014-10-10
- Target Recruit Count
- 60
- Registration Number
- NCT01552772
- Locations
- 🇺🇸
Collaborative Neuroscience Network, Garden Grove, California, United States
🇺🇸Compass Research, LLC, Orlando, Florida, United States
🇺🇸CNRI-San Diego, San Diego, California, United States
Open-label Study to Compare Hospitalization Rates of Schizophrenic Patients Treated With Oral Antipsychotics Versus IM Depot Aripiprazole
Phase 3
Terminated
- Conditions
- Schizophrenia
- Interventions
- First Posted Date
- 2012-01-12
- Last Posted Date
- 2015-03-04
- Target Recruit Count
- 30
- Registration Number
- NCT01509053
© Copyright 2025. All Rights Reserved by MedPath